Skip to main content
Download PDF

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma

Journal for ImmunoTherapy of Cancer volume 3, Article number: P129 (2015) Cite this article

Background

The efficacy and safety of high dose IL-2 therapy in patients with brain metastases due to renal cell carcinoma is not well characterized.

Methods

Data were prospectively collected in a registry of 371 patients with RCC receiving high-dose IL-2, including 18 patients with a history of brain metastases who had undergone treatment for the brain metastases with radiation therapy or surgery. The median interval between the diagnosis of brain metastases and the start of IL-2 therapy was 7.0 months (range 1-116 months). Median overall survival in patients with brain metastases was 15.3 (95% CI 8.0 to not evaluable) months, as compared to 48.0 (95% CI 39.2 to 61.5) months in RCC patients without any history of brain metastases.

Results

The response to IL-2 in the extra-cranial disease was assessed. In patients with brain metastases, 0/18 (0%) had a complete response, 1/18 (5.6%) had a partial response, and 4/18 (22.2%) had stable disease, whereas in patients without brain metastases, 15/353 (4.5%) achieved a complete response, 45/353 (13.4%) achieved a partial response, and 117/353 (34.8%) had stable disease. During the first course of IL-2, neurologic adverse events were reported in 6 subjects (2 events of confusion, 2 events of mental fatigue, 1 event of rigors, and 1 event of anxiety), but no seizures or intracranial hemorrhages were reported.

Conclusions

While the efficacy of IL-2 in this population is limited, the neurologic adverse event rate is acceptably low; in carefully selected patients with brain metastases, IL-2 may be considered as a therapeutic option but response rates may be lower than in patients without CNS disease based on this limited cohort analysis.

Author information

Authors and Affiliations

  1. Rutgers-Robert Wood Johnson Medical School, New Brunswick, NH, USA

    Ashwin Chandar

  2. Cancer Institute of New Jersey, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Ann W Silk, Mark Stein, Janice Mehnert & Howard L Kaufman

  3. Loyola University Medical Center, Division of Hematology Oncology, Maywood, IL, USA

    Joseph I Clark

  4. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA

    Gregory A Daniels

  5. The Cytokine Working Group; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

    David F McDermott

  6. Duke Cancer Center, Durham, NC, USA

    Michael Morse

  7. University of Southern California, Los Angeles, Los Angeles, CA, USA

    Michael KK Wong

  8. Department of Neurosurgery, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Shabbar Danish

  9. Prometheus Laboratories Inc., San Diego, CA, USA

    Sandra Aung

Authors
  1. Ashwin Chandar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann W Silk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph I Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory A Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David F McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Morse
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael KK Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mark Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Janice Mehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shabbar Danish
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sandra Aung
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Howard L Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chandar, A., Silk, A.W., Clark, J.I. et al. Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma. j. immunotherapy cancer 3 (Suppl 2), P129 (2015). https://doi.org/10.1186/2051-1426-3-S2-P129

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2051-1426-3-S2-P129

Keywords